"All-Med" Specjalistyczna Opieka Medyczna Medyczny Instytut Badawczy Marek Jutel
- Address
- "All-Med" Specjalistyczna Opieka Medyczna Medyczny Instytut Badawczy Marek Jutel, ul. Hallera 95, 53201 Wroclaw, Poland
Respiratory Tract Diseases
The All-Med Pulmonology department in Wroclaw is advancing research to improve care for patients with asthma. Current studies assess a biologic agent combined with standard inhaled therapy to lower the rate of severe exacerbations.
- Biologic augmentation of inhaled corticosteroid therapy
- Comparative effectiveness of treatment escalation strategies
- Patient‑reported outcome measures in uncontrolled asthma
The site works with a dedicated investigator, follows European regulatory standards, and welcomes adolescent and adult participants.
Immune System Diseases
Researchers at the Marek Jutel Institute are conducting a first‑in‑human trial of a new compound for rheumatoid arthritis, focusing on safety and early efficacy signals to broaden therapeutic options for this autoimmune condition.
- First‑in‑human safety assessment of novel molecules
- Pharmacodynamic monitoring in autoimmune disease
- Integration of biomarkers for disease activity
Based in Wroclaw, Poland, the center provides a supportive environment for participants and contributes to global efforts against immune‑mediated disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in "All-Med" Specjalistyczna Opieka Medyczna Medyczny Instytut Badawczy Marek Jutel
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy of Dupilumab with Medium-Dose ICS/LABA vs. High-Dose ICS/LABA in Adolescents and Adults with Uncontrolled Asthma | Regeneron Pharmaceuticals Inc. | Phase III | Not Recruiting | Mar 2025 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dupilumab | 1 | Unknown | 2025-03-11 | 2025-03-11 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.